Benactyzine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Benactyzine
Benactyzine.svg
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.005.568 Edit this at Wikidata
Chemical and physical data
Formula C20H25NO3
Molar mass 327.417 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Benactyzine is an anticholinergic drug that was used as an antidepressant in the treatment of depression and associated anxiety before it was pulled from the U.S. market by the FDA due to its ineffectiveness.[1]

Its use for these indications was limited by side effects such as dry mouth and nausea, and at high doses it can cause more severe symptoms such as deliriant and hallucinogenic effects.[1]

Brand names have included: Suavitil, Phebex, Phobex, Cedad, Cevanol, Deprol, Lucidil, Morcain, Nutinal, Parasan. While there was some tentative evidence of effectiveness when combined with meprobamate, with the medication no longer available it is not clinically important.[2]

History[edit]

Benactyzine was brought to market in the US in 1957 by Merck under the tradename, Suavitil.[3]

References[edit]

  1. ^ a b Shorter, E., Looking backwards: a possible new path for drug discovery in psychopharmacology. Nat Rev Drug Discov 2002, 1 (12), 1003–1006.
  2. ^ DeBattista, Alan F. Schatzberg, Jonathan O. Cole, Charles (2010). Manual of clinical psychopharmacology (7th ed.). Washington, DC: American Psychiatric Pub. p. 423. ISBN 978-1-58562-377-8. 
  3. ^ Smith, Mickey C., PhD. Principles of Pharmaceutical Marketing, Third Edition. 3rd ed. New York: Routledge, 2013. Print. ISBN 978-1-317-94071-5

External links[edit]